CAR T-Cell Therapy Treatment

CAR T-cell therapy is one form of a new and very promising way of immunotherapy in that it takes one's T-cells for identifying the cancerous cells to eliminate them. Here, in this particular approach, only those modified T-cells are utilized for fighting cancers through direct accuracy upon certain B-cell lymphomas' subtypes. This particular change increases immunity power of the human body that easily attacks the cancerous cells of lymphomas.

Book an Appointment

About CAR T-Cell Therapy

A part of the patient's T-cells is drawn out from the blood using a procedure called apheresis. In a specialized laboratory, these cells are genetically engineered to fit them with specific structures that are called chimeric antigen receptors (CARs) on their surface. These CARs are proteins tailored to bind to a preselected target on the surface of cancer cells. In the case of therapies currently approved, the target is the CD19 protein, which is present on both normal and malignant B-cells.

Indications for CAR T-Cell Therapy

CAR T-Cell Therapy has shown promising results for patients with:

B-cell acute lymphoblastic leukemia (ALL)
Diffuse large B-cell lymphoma (DLBCL)
Primary mediastinal large B-cell lymphoma (PMBCL)
Mantle cell lymphoma (MCL)
Follicular lymphoma (FL)

This therapy is generally recommended for patients who have not responded well to traditional treatments like chemotherapy or radiation, or those who have experienced relapses.

Benefits of CAR T-Cell Therapy

Targeted Treatment: CAR T-Cell Therapy specifically targets cancer cells, reducing damage to healthy cells.
Long-lasting Effects: Many patients experience durable responses, and some even achieve complete remission.
Personalized Approach: This therapy is tailored to each patient’s unique immune system.

Procedure of CAR T-Cell Therapy

CAR T-Cell Process

Each person receives a unique batch of CAR T-cells. While the CAR T-cells are being produced (3-6 weeks), you might also receive other therapies, like chemotherapy (bridging therapy), to keep your lymphoma under control.

T-cell collection: A sample of blood is taken from the patient. The white blood cells, such as T-cells, are separated and the remaining blood is returned to the circulation of the patient through apheresis, which is similar to stem cell collection. The T-cells of the patient are sent to the laboratory for processing.

Manufacture of CAR T-cells: To allow the T-cells to find and eliminate the cancer cells, the T-cells are gene-manipulated, that is, changed. Modified T-cells are a new name for CAR T-cells. A million of the patient's CAR T-cells is manufactured, and then are frozen. Then CAR T-cells are sent to the patient's medical treatment center. Weeks may lapse in this process.

Chemotherapy: To decrease the number of healthy T-cells in the patient so that there will be available space for CAR T cells to multiply, chemotherapy commonly known as lymphodepletion will be administered. Generally it is cyclophosphamide and fludarabine.

Cell Infusion: The patient's CAR T cells are thawed and put back into the patient's bloodstream, similar to a blood or stem cell transfusion.

Inside the patient: The CAR-T cells multiply rapidly in the patient's bloodstream. The CAR-T cells find and kill lymphoma cells. The CAR T cells remain in the bloodstream and can attack lymphoma if it comes back.

Recovery: Patients are closely monitored during and after treatment. The recovery period for patients who undergo CAR T-cell therapy is approximately 2-3 months. During this time, patients are tested for side effects and treatment success. For at least the first 30 days after discharge, patients must remain close to the treating hospital (maximum 20 minutes) for regular follow-ups and emergency care if necessary.